Brought to you by 
Synthes and Lilly team up in orthopedics drug/biomaterials deal
27 May 2015
Executive Summary
Musculoskeletal device company Synthes Inc. and Eli Lilly & Co. are joining forces to develop new treatments for orthopedic conditions including osteoporosis and bone fractures.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Site Specific
-
Drug Delivery
-
Medical Devices
- Biomaterials
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Synthes and Lilly team up in orthopedics drug/biomaterials deal
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice